Clinical Trial Update: Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing oral tebipenem pivoxil hydrobromide (SPR994) to IV ertapenem in complicated urinary tract infection and acute pyelonephritis has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Urinary Tract Infection
• Pyelonephritis

Drugs mentioned

• ERTAPENEM (ertapenem)
• Tebipenem pivoxil hydrobromide (SPR994) (tebibem pivoxil hydrobromide)

Snippet

Sponsor: Spero Therapeutics | Conditions: Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Status: COMPLETED | Results posted: 2022-07-25